By combining advanced AI and biomedical data, Knowing01 is transforming research on complex datasets. For four years, the team has been developing software to analyze biomedical markers in the context of large datasets. The AI-powered platform helps pharma and biotech companies as well as researchers make better decisions in disease research and drug development. According to founder Nikola Müller, this makes 80 to 95 percent of previously unused biomedical data accessible. The user-friendly solution is designed to reduce costs and risks in drug development.
The concept has now also convinced investors who are providing the startup with a six-figure sum. In addition to Backbone Ventures, various business angels from the DACH region invested, including Julia Ju, Veronika Chrestin, Björn Schäfer, and Johannes Stiber. The financing enables Knowing01 to accelerate the development of its software for contextualizing molecular data and expand its team.
Last year, the company launched its first product on the European biotech market. The proprietary AI-powered multiomics platform enables researchers to gain insights from existing data using a scalable in-silico approach. This is intended to achieve better research results with lower error rates. Multiomics integrates various biological data types such as genomics, proteomics, and transcriptomics. This creates a comprehensive overview of biological processes.
Nikola Müller, founder and CEO of Knowing01, explains:
“With our solution, we enable scientists to tap into unused data sources and make more informed decisions in drug development.”
